BEAM · NASDAQ · Biotechnology

Beam Therapeutics (BEAM)

Develops base-edited medicines for sickle cell disease and inherited metabolic disorders.

$25.93
After hours+0.01 (+0.04%)
At close$25.92(+2.61%)